Population-level persistence of immunity 2 years after the PsA-TT mass-vaccination campaign in Mali

Clinical Infectious Diseases

Volumn 61, Issue , 2015, Pages S547-S553

  Basta, Nicole E ^a,b   Borrow, Ray ^c   Berthe, Abdoulaye ^d   Dembélé, Awa Traoré Eps ^d   Onwuchekwa, Uma ^d   Townsend, Kelly ^c   Boukary, Rahamatou M ^c   Mabey, Lesley ^c   Findlow, Helen ^c   Bai, Xilian ^c   Sow, Samba O ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d MINISTÈRE DE LA SANTÉ   (Mali)

Author keywords

Africa; immunity; meningococcal vaccines; seroprevalence

Indexed keywords

COMPLEMENT; IMMUNOGLOBULIN G; MENINGOCOCCUS VACCINE; BACTERIUM ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CHILD; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEOMETRIC MEAN CONCENTRATION; GEOMETRIC MEAN TITER; HOUSEHOLD; HUMAN; IMMUNITY; MALE; MALI; MASS IMMUNIZATION; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PARAMETERS; POPULATION; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; SCHOOL CHILD; SEROPREVALENCE; SERUM BACTERICIDAL ANTIBODY ASSAY; STATISTICAL ANALYSIS; YOUNG ADULT; ANIMAL; BLOOD; IMMUNOLOGY; INFANT; MENINGITIS, MENINGOCOCCAL; SERUM BACTERICIDAL ACTIVITY; TIME FACTOR;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; MALI; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP A; SEROEPIDEMIOLOGIC STUDIES; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; YOUNG ADULT;

EID: 84947572467     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ602     Document Type: Article

References (39)

1. LaForce FM, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009; 27(suppl 2):B13-9.
2. LaForce FM, Konde K, Viviani S, Preziosi MP. The Meningitis Vaccine Project. Vaccine 2007; 25(suppl 1):A97-100.
3. Jodar L, LaForce FM, Ceccarini C, Aguado T, Granoff DM. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 2003; 361:1902-4.
4. Okoko BJ, Idoko OT, Adegbola RA. Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa. Vaccine 2009; 27:2023-9.
5. LaForce FM, Okwo-Bele JM. Eliminating epidemic group A meningococcal meningitis in Africa through a new vaccine. Health Affairs 2011; 30:1049-57.
6. Kshirsagar N, Mur N, Thatte U, et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 2007; 25(suppl 1):A101-7.
7. Hirve S, Bavdekar A, Pandit A, et al. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial. Vaccine 2012; 30:6456-60.
8. Sow SO, Okoko BJ, Diallo A, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011; 364:2293-304.
9. Meningitis Vaccine Project. News digest 42. Quarter 4, 2014. Available at: http://www.meningvax.org/files/MVP-newsdigest-2014-Q4-42-EN.pdf. Accessed January 2015.
10. Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal conjugate vaccine (MenAfriVac®) on serogroup A meningococcal meningitis and carriage in Chad: a community study. Lancet 2014; 383:40-7.
11. Gamougam K, Daugla DM, Toralta J, et al. Continuing effectiveness of serogroup A meningococcal conjugate vaccine, Chad, 2013. Emerg Infect Dis 2015; 21:115-8.
12. Kristiansen PA, Diomande F, Ba AK, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2013; 56:354-63.
13. Kristiansen PA, Ba A, Ouedraogo AS, et al. Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac. BMC Infect Dis 2014; 14:663.
14. Dakar Discussion Group on Priorities for Research on Epidemic Meningococcal Disease in Africa;Altmann D, Aseffa A, Bash M, et al. Priorities for research onmeningococcal disease and the impact of serogroup Avaccination in the African meningitis belt. Vaccine 2013; 31:1453-7.
15. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369: 2196-210.
16. Dellicour S, Greenwood B. Systematic review: impact of meningococcal vaccination on pharyngeal carriage of meningococci. Trop Med Int Health 2007; 12:1409-21.
17. PatelM, Lee CK. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. Cochrane Database Syst Rev 2005; doi:10.1002/14651858.CD001093.
18. de Whalley PC, Snape MD, Plested E, et al. Long-Derm seroprotection after an adolescent booster meningococcal serogroup C vaccination. Arch Dis Child 2013; 98:686-91.
19. Khatami A, Peters A, Robinson H, et al. Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood. Clin Vaccine Immunol 2011; 18:2038-42.
20. Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62(RR-2):1-28.
21. Public Health England. Changes to the meningococcal C conjugate (MenC) vaccine schedule 2013-2015. Available at: https://www.gov. uk/government/uploads/system/uploads/attachment-data/file/336171/ MenC-information-for-healthcare-professionals-V7-.pdf. Accessed January 2015.
22. Pollard AJ, Green C, SadaranganiM, Snape MD. Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease. Arch Dis Child 2013; 98:248-51.
23. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-7.
24. Borrow R, Abad R, Trotter C, van der Klis FR, Vazquez JA. Effectiveness of meningococcal serogroup C vaccine programmes. Vaccine 2013; 31:4477-86.
25. World Health Organization. Global health observatory data repository. Number of suspected meningitis cases reported. Data by country. Available at: http://apps.who.int/gho/data/node.main.179?lang=en. Accessed January 2015.
26. World Health Organization. Global Alert and Response (GAR) epidemiological information. Meningitis season reports and weekly reports. Available at: http://www.who.int/csr/disease/meningococcal/epidemiological/ en/. Accessed January 2015.
27. Basta NE, Borrow R, Berthe A, et al. Higher tetanus toxoid immunity 2 years after PsA-DT introduction in Mali. Clin Infect Dis 2015; 61(suppl 5):S578-85.
28. Maslanka SE, Gheesling LL, Libutti DE, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 1997; 4:156-67.
29. Carlone GM, Frasch CE, Siber GR, et al. Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay. J Clin Microbiol 1992; 30:154-9.
30. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969; 129:1307-26.
31. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003; 10:780-6.
32. Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-Detanus toxoid candidate conjugate (MenACWY-DT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009; 27:161-8.
33. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 2005; 23:2222-7.
34. Frasch CE, Preziosi MP, LaForce FM. Development of a group A meningococcal conjugate vaccine, MenAfriVac. Hum Vaccin Immunother 2012; 8:715-24.
35. Organisation mondiale de la sante. Programme elargi de vaccination. Evaluation de la campagne de vaccination contre la meningite avec le vaccine MenAfriVac 2eme phase, dans les regions de Koulikoro, Segou et le district de Bamako au Mali en 2010, Malian Ministry of Health, 2011.
36. Idoko OT, Okolo SN, Plikaytis B, et al. The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines. Vaccine 2014; 32:4220-7.
37. Norheim G, Aseffa A, Yassin MA, et al. Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7. Clin Vaccine Immunol 2007; 14:451-63.
38. Trotter CL, Yaro S, Njanpop-Lafourcade BM, et al Seroprevalence of bactericidal, specific IgG antibodies and incidence ofmeningitis due to group A Neisseriameningitidis byage inBurkinaFaso 2008.PLoSOne2013 8 e55486.
39. Klein SL, Marriott I, Fish EN. Sex-based differences in immune function and responses to vaccination. Trans R Soc TropMed Hyg 2015; 109:9-15.